First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 0.83 USD Market Closed
Updated: Oct 1, 2023

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ADC Therapeutics SA

Revenue
184m USD
Cost of Revenue
-2.2m USD
Gross Profit
182m USD
Operating Expenses
-284.9m USD
Operating Income
-102.7m USD
Other Expenses
-78.6m USD
Net Income
-181.3m USD

Margins Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
66.9m USD
99%
-58%
-74%
US
Abbvie Inc
NYSE:ABBV
263B USD
70%
36%
15%
US
Amgen Inc
NASDAQ:AMGN
144B USD
74%
37%
30%
US
Gilead Sciences Inc
NASDAQ:GILD
93.5B USD
79%
31%
20%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
89.6B USD
88%
42%
35%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
89.6B USD
87%
41%
36%
AU
CSL Ltd
ASX:CSL
122B AUD
51%
24%
16%
US
Seagen Inc
NASDAQ:SGEN
39.8B USD
76%
-33%
-34%
US
Moderna Inc
NASDAQ:MRNA
39.4B USD
72%
49%
43%
US
Biogen Inc
NASDAQ:BIIB
37.2B USD
77%
30%
27%
NL
argenx SE
NASDAQ:ARGX
27.5B USD
93%
-175%
-173%
Country CH
Market Cap 66.9m USD
Gross Margin
99%
Operating Margin
-58%
Net Margin
-74%
Country US
Market Cap 263B USD
Gross Margin
70%
Operating Margin
36%
Net Margin
15%
Country US
Market Cap 144B USD
Gross Margin
74%
Operating Margin
37%
Net Margin
30%
Country US
Market Cap 93.5B USD
Gross Margin
79%
Operating Margin
31%
Net Margin
20%
Country US
Market Cap 89.6B USD
Gross Margin
88%
Operating Margin
42%
Net Margin
35%
Country US
Market Cap 89.6B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
36%
Country AU
Market Cap 122B AUD
Gross Margin
51%
Operating Margin
24%
Net Margin
16%
Country US
Market Cap 39.8B USD
Gross Margin
76%
Operating Margin
-33%
Net Margin
-34%
Country US
Market Cap 39.4B USD
Gross Margin
72%
Operating Margin
49%
Net Margin
43%
Country US
Market Cap 37.2B USD
Gross Margin
77%
Operating Margin
30%
Net Margin
27%
Country NL
Market Cap 27.5B USD
Gross Margin
93%
Operating Margin
-175%
Net Margin
-173%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
ADC Therapeutics SA
NYSE:ADCT
66.9m USD
-122%
-27%
-25%
-74%
US
Abbvie Inc
NYSE:ABBV
263B USD
63%
6%
19%
16%
US
Amgen Inc
NASDAQ:AMGN
144B USD
173%
11%
16%
16%
US
Gilead Sciences Inc
NASDAQ:GILD
93.5B USD
27%
9%
17%
11%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
89.6B USD
25%
19%
26%
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
89.6B USD
21%
16%
21%
22%
AU
CSL Ltd
ASX:CSL
122B AUD
14%
7%
12%
12%
US
Seagen Inc
NASDAQ:SGEN
39.8B USD
-26%
-20%
-25%
-39%
US
Moderna Inc
NASDAQ:MRNA
39.4B USD
50%
33%
52%
57%
US
Biogen Inc
NASDAQ:BIIB
37.2B USD
20%
11%
14%
13%
NL
argenx SE
NASDAQ:ARGX
27.5B USD
-27%
-24%
-27%
-132%
Country CH
Market Cap 66.9m USD
ROE
-122%
ROA
-27%
ROCE
-25%
ROIC
-74%
Country US
Market Cap 263B USD
ROE
63%
ROA
6%
ROCE
19%
ROIC
16%
Country US
Market Cap 144B USD
ROE
173%
ROA
11%
ROCE
16%
ROIC
16%
Country US
Market Cap 93.5B USD
ROE
27%
ROA
9%
ROCE
17%
ROIC
11%
Country US
Market Cap 89.6B USD
ROE
25%
ROA
19%
ROCE
26%
ROIC
42%
Country US
Market Cap 89.6B USD
ROE
21%
ROA
16%
ROCE
21%
ROIC
22%
Country AU
Market Cap 122B AUD
ROE
14%
ROA
7%
ROCE
12%
ROIC
12%
Country US
Market Cap 39.8B USD
ROE
-26%
ROA
-20%
ROCE
-25%
ROIC
-39%
Country US
Market Cap 39.4B USD
ROE
50%
ROA
33%
ROCE
52%
ROIC
57%
Country US
Market Cap 37.2B USD
ROE
20%
ROA
11%
ROCE
14%
ROIC
13%
Country NL
Market Cap 27.5B USD
ROE
-27%
ROA
-24%
ROCE
-27%
ROIC
-132%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Other Stocks